GMAB Stock Forecast & Price Target

Genmab is viewed positively because it combines proven profitability with durable commercial momentum, as 2Q26 net earnings of $4.91 per diluted share exceeded expectations and total revenue of $1.155B was 5% above Street consensus, while it also ended 2Q26 with about $1.5B in cash, cash equivalents, and marketable securities that strengthens its balance-sheet resilience. The outlook is further supported by the company’s core royalty engine, especially Darzalex, whose $966M in royalty revenue and strong growth trajectory continue to anchor results, alongside rising contribution from Epkinly and net product sales of $145M, which together helped Genmab raise 2026 financial guidance and project full-year 2026 net earnings of $14.84 per diluted share. Beyond current earnings power, the company has multiple near- and medium-term catalysts from a broad oncology pipeline, including key readouts for epcoritamab in 1L DLBCL and Rina-S across several tumor types, giving Genmab multiple shots at incremental value creation while reducing reliance on any single asset.

Genmab is viewed negatively because its valuation remains heavily dependent on DARZALEX, a mature franchise whose slowing sales are explicitly cited as a key risk, while the rest of the portfolio still requires substantial clinical and commercial execution to offset that concentration. Even with diversified assets such as epcoritamab, tisotumab vedotin, teclistamab, and petosemtamab, the outlook is constrained by meaningful probabilities of failure or lower-than-expected penetration, alongside the risk of negative readouts from EPKINLY trials, regulatory setbacks, and emerging competition. The company also faces financing and dilution concerns tied to the MRUS acquisition and associated debt, while the DCF assumptions themselves imply limited upside support, using an 8.0% to 8.5% discount rate, a 1.5% to 2% terminal growth rate, and a 23% effective tax rate through 2045.